1. Ly, H. (2022, September 28). Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants with Early Alzheimer’s Disease. Available online: https://www.eisai.com/news/2022/news202271.html.
2. Zhong, X., and D’Antona, A.M. (2021). Recent advances in the molecular design and applications of multispecific biotherapeutics. Antibodies, 10.
3. Affibody Molecules in Biotechnological and Medical Applications;Frejd;Trends Biotechnol.,2017
4. Affibody, A.B. (2022, October 31). ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented during 2022 European Alliance of Associations for Rheumatology Congress. Available online: https://www.affibody.se/affibody-acelyrin-and-inmagene-biopharmaceuticals-announce-data-from-global-phase-2-trial-of-izokibep-in-patients-with-psoriatic-arthritis-presented-during-2022-european-alliance-of-associations-for-2/.
5. Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides;Jonsson;J. Biotechnol.,2007